Detalhe da pesquisa
1.
Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Int J Cancer
; 153(5): 1080-1095, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37293858